Bull of the Day: Eli Lilly (LLY)

Eli Lilly reported a strong Q2 2024 with revenue up 36% and EPS rising 68% year-over-year, beating estimates by 42% and prompting a $3 billion increase to full-year revenue guidance. The company’s leadership in the GLP-1 weight-loss market (Mounjaro), FDA approvals (Kisunla, Jaypirca) and positive tirzepatide data underpin analysts’ upward revisions (estimates raised as much as 23.4% in two months), supporting a 23% revenue growth projection for the year and a multi-year EPS CAGR of ~33.3%. Trading at ~38.3x next-year earnings with a ~$535 billion market cap, the stock is presented as a defensive name with significant upside if GLP-1 market expansion (forecast ~20% CAGR to $133B by 2030) and pipeline successes continue.

Analysis

Market structure: Eli Lilly (LLY) is the primary beneficiary of accelerating GLP‑1 demand (market to $133bn by 2030) — suppliers (CDMOs), specialty pharmacies and select CROs also gain; payers, smaller competitors and weight‑loss clinics face margin pressure. Lilly’s current 38.3x forward P/E prices robust execution; near‑term supply constraints and formulary access are the main mechanisms that can cap growth despite strong demand, suggesting upside is concentrated in product mix and label expansion rather than broad pricing power.

Risk assessment: Key tail risks are (1) regulatory/payer price interventions (10–25% chance) that could shave 15–40% off peak revenues, (2) safety signals in expanded indications (5–10% chance) that would cause >50% short‑term re‑rating, and (3) faster competitive share loss to Novo Nordisk (~10–30% share shift by 2030). Timing: days—earnings/IV repricing; weeks–months—payer coverage and supply announcements; years—label expansion and peak sales realization.

Trade implications: Tactical allocation: favor LLY as a growth‑defensive hybrid but hedge idiosyncratic risk. Use a 2–3% long position size or 9–12 month 25% OTM call spreads to express upside; hedge with 4–6 month puts if payer headlines surface. Consider a relative trade long LLY / short NVO (equal dollar delta) to isolate company execution vs. class dynamics.

Contrarian angles: Consensus underestimates payer resistance and the probability of margin normalization; markets may be underpricing a scenario where price rebates/step edits compress realized ASPs by >10–20%. Historical parallels (PCSK9, SGLT2 uptake) show medical adoption can be rapid clinically but stalled commercially by access controls — if Lilly’s YOY Mounjaro growth falls <30% on payer edits, sentiment will flip quickly.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in LLY equity within 30 days (size to target 12‑month upside), and simultaneously buy 4–6 month puts at ~10–15% OTM equal to 25–50% of the position to limit downside against a regulatory/payer shock.
• If bullish but want defined risk: buy a 9–12 month LLY call spread 25% OTM (buy 25% OTM calls, sell 50% OTM) sized to 1–2% portfolio exposure; roll or convert to stock on sustained quarterly beats or new indication approvals.
• Run a pair trade: go long LLY and short NVO (Novo Nordisk) equal dollar delta for 6–18 months to isolate Lilly’s execution; increase short if Lilly’s market share gains vs. Novo exceed 5 percentage points in one quarter.
• Set explicit monitoring triggers: reduce LLY exposure by 50% if (a) quarterly Mounjaro growth <30% YoY, (b) CMS/payer issues within 60 days imposing step edits, or (c) forward P/E reverts to <30x — increase exposure by 50% if Mounjaro growth >50% YoY and new label approvals (heart failure/Alzheimer’s) occur within 12 months.